Prevention

Provention Bio is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to intercept and prevent immune-mediated diseases. The company's flagship product, TZIELD (teplizumab-mzwv), is the first and only FDA-approved treatment indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older. Beyond diabetes, Provention Bio maintains a pipeline of candidates targeting other autoimmune conditions such as celiac disease and systemic lupus erythematosus. In April 2023, the company was acquired by Sanofi, significantly expanding the reach of its immunology portfolio.